A primary cause of cardiovascular disease (CVD), or atherosclerosis, now referred to as atherothrombosis, is the hardening and narrowing of the body’s arteries.
Atherothrombosis is characterized by a sudden, unpredictable, atherosclerotic plaque disruption, leading to platelet activation and thrombus (blood clot) formation. The blood clot will most likely enter the bloodstream, partially or totally blocking the blood flow in the artery and causing a local decrease in oxygen supply (ischemia) to the target organ.
When plaque formation progresses to a stage where the artery is completely blocked, the lack of oxygen – rich blood to the organ may cause severe cell damage or cell death.
Plaque rupture is generally accompanied by an acute thrombotic phenomenon leading to the abrupt closure of the vessel, and subsequently leads to ischemic events in the arteries of the brain, heart, kidneys, legs and arms. Therefore, atherothrombosis is the underlying condition that results in serious disease and complications such as coronary artery, peripheral aterial and cerebrovascular diseases.
In this context, ICAN aims to develop personalized treatments for these chronic troubles.